Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?

Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it... Cardiovascular Research (2009) 84, 341–342 Editorial doi:10.1093/cvr/cvp339 Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work? Stephan Immenschuh Institute for Transfusion Medicine, Hanover Medical School, Carl-Neuberg-Str. 1, 30625 Hanover, Germany Online publish-ahead-of-print 9 October 2009 This editorial refers to ‘CB1 and CB2 cannabinoid recep- development and progression of atherosclerosis, and Han tors differentially regulate the production of reactive et al. show that cannabinoid receptor expression on these oxygen species by macrophages’ by K.H. Han et al., cells is regulated in a species-specific manner. Expression pp. 378–386, this issue. of CB1 and CB2 receptors in mouse and human shows a dis- tinct pattern of regulation in response to pro-inflammatory The endocannabinoid system is a physiological signalling and pro-atherogenic stimuli that is dependent on the network that has attracted major attention in recent years degree of differentiation of monocytic cells. Importantly, because of its therapeutic potential for the treatment of the differential expression of CB1 and CB2 receptors on various pathological conditions, including cardiovascular mononuclear cells is functionally significant. The ratio of disease. More specifically, targeted modulation of the CB1:CB2 receptor expression regulates the inflammatory major receptors of this system, the G-protein-coupled can- activity of these cells and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiovascular Research Oxford University Press

Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?

Cardiovascular Research, Volume 84 (3) – Dec 1, 2009

Loading next page...
 
/lp/oxford-university-press/endocannabinoid-signalling-as-an-anti-inflammatory-therapeutic-target-qCOEvcqOmv
Publisher
Oxford University Press
Copyright
© Published by Oxford University Press.
Subject
EDITORIALS
ISSN
0008-6363
eISSN
1755-3245
D.O.I.
10.1093/cvr/cvp339
Publisher site
See Article on Publisher Site

Abstract

Cardiovascular Research (2009) 84, 341–342 Editorial doi:10.1093/cvr/cvp339 Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work? Stephan Immenschuh Institute for Transfusion Medicine, Hanover Medical School, Carl-Neuberg-Str. 1, 30625 Hanover, Germany Online publish-ahead-of-print 9 October 2009 This editorial refers to ‘CB1 and CB2 cannabinoid recep- development and progression of atherosclerosis, and Han tors differentially regulate the production of reactive et al. show that cannabinoid receptor expression on these oxygen species by macrophages’ by K.H. Han et al., cells is regulated in a species-specific manner. Expression pp. 378–386, this issue. of CB1 and CB2 receptors in mouse and human shows a dis- tinct pattern of regulation in response to pro-inflammatory The endocannabinoid system is a physiological signalling and pro-atherogenic stimuli that is dependent on the network that has attracted major attention in recent years degree of differentiation of monocytic cells. Importantly, because of its therapeutic potential for the treatment of the differential expression of CB1 and CB2 receptors on various pathological conditions, including cardiovascular mononuclear cells is functionally significant. The ratio of disease. More specifically, targeted modulation of the CB1:CB2 receptor expression regulates the inflammatory major receptors of this system, the G-protein-coupled can- activity of these cells and

Journal

Cardiovascular ResearchOxford University Press

Published: Dec 1, 2009

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off